Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.60 +2.31%
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.04 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $115.2 million versus the consensus estimate of $126.15 million.
GUIDANCE:
Acadia Pharma sees Q3 2021 revenue of $480-515 million, versus the consensus of $527.7 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
